Hepatocellular carcinoma (HCC) is a type of liver cancer that arises from the cell of liver or hepatocytes. This condition can be diagnosed by using ultrasound, MRI, CT scan, and liver biopsy. Treatment for hepatocellular carcinoma mainly includes radiation therapy, ablation therapy combined with chemotherapy and targeted drug therapy. Due to the poor prognosis of the condition, the mortality rate is approximately the same as the incidence rate. Hence, early detection of this cancer is important for improving the survival rate of the patient.
Download the free Sample copy of Report with Table of Contents and Figures @ https://www.coherentmarketinsights.com/insight/request-pdf/1596
Market Dynamics
The growing incidence of global hepatocellular carcinoma cases around the globe is a major factor augmenting market growth. According to the research by the International Journal of Cancer Research and Treatment, 2014, HCC is the sixth most common type of cancer worldwide and the third most common cause of death worldwide, fifth for men and eighth for women. The disease accounts for more than 5% of all cancers and 80-90% of primary liver cancers. Also, according to Addis Ababa University, 2017, hepatocellular carcinoma (HCC) accounted for 854,000 new cases of liver cancer and 810,000 related deaths in 2015.
Moreover, growing clinical research along with the approval of novel drugs by the regulatory agencies for treating hepatocellular carcinoma is projected to foster the growth of the market. For instance, in April 2017, the U.S. Food & Drug Administration expanded the indications of regorafenib (Stivarga) manufactured by Bayer HealthCare Pharmaceuticals Inc., for treatment of patients with hepatocellular carcinoma. The therapy showed significant improvement in survival for patients after the failure of standard treatments. Also, in 2017, the U.S. FDA granted accelerated approval for nivolumab (Opdivo) drug developed by Bristol-Myers Squibb for the treatment of hepatocellular carcinoma.
However, the side effects associated with the drugs such as anemia, constipation, low white blood cell count, pneumonia are expected to hamper the market growth.
Regional Dynamics
Regional segmentation of the global hepatocellular carcinoma drugs market by Coherent Market Insights comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global hepatocellular carcinoma drugs market over the forecast period, and this can be attributed to rising prevalence of the disease and the growing number of clinical trials undertaken by the manufacturers to address the unmet medical needs of the patients in the region. According to the survey by the Health Science Department, University of California, Los Angeles, (UCLA), 2017, hepatocellular carcinoma (HCC) accounts for three-quarters of liver cancers in the U.S. with an estimated 40,000 Americans diagnosed with liver cancer in 2017 and more than 28,000 deaths are reported from the disease. Also, in April 2018, Eli Lilly and Company completed the Phase 3 research study of Cyramza (ramucirumab) as a single agent in the second-line treatment of people with hepatocellular carcinoma, also known as liver cancer.
The Asia Pacific is expected to gain significant traction in the global hepatocellular carcinoma drugs market owing to the growing number of research and development activities undertaken by the manufacturers in the region in order to develop effective therapies for the treatment of Hepatocellular carcinoma. For instance, in February 2017, Daiichi Sankyo, a pharmaceutical company in Japan completed the Phase-3 study of tivantinib indicated for patients with hepatocellular carcinoma treated with other therapies.
Competitive Analysis
The manufactures are adopting various strategic collaborations to jointly develop and commercialize immunotherapies for treating a broad range of tumors. For instance, in 2014, Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd. signed a strategic collaboration agreement to jointly develop and commercialize multiple immunotherapies as single agents and combination therapies with Opdivo, to help address the unmet medical needs of patients with cancer in Japan, South Korea, and Taiwan. Also, in 2015, Novartis Pharmaceuticals initiated the Phase 2 trials to compare the safety and efficacy for dovitinib and sorafenib in adult patients with advanced hepatocellular carcinoma.
Key players operating in the global hepatocellular carcinoma drugs market include Novartis Pharmaceuticals, Bayer AG, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson, Celgen Corporation, Amgen Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.
Purchase a copy of Hepatocellular Carcinoma Drugs Market Report: https://www.coherentmarketinsights.com/insight/buy-now/1596
Market Taxonomy
Based on drug class
- PD-1/PD-L1 Inhibitors
- Nivolumab (Opdivo)
- Tyrosine Kinase Inhibitors
- Sorafenib (Nexavar)
- Regorafenib (Stivarga)
Based on end-user
- Hospital
- Clinics
- Cancer Rehabilitation Centers
- Ambulatory Surgical Centers
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Name: Mr. Raj Shah
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com
